Open-label study in patients with partial lipodystrophy-associated NASH featured in oral presentation
Recent Press Releases
Vancouver, British Columbia, March 31, 2017 – Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corrigan will serve as a member of the compliance committee.
- Company Reiterates FY 2017 Total Net Product Sales Expected to be
Between $155 and $165 million
- Global Expansion Plans for Metreleptin Opportunity Underway